Phase 1 study of safety, pharmacokinetics, and antiviral activity of <scp>SARS‐CoV</scp> ‐2 neutralizing monoclonal antibody <scp>ABBV‐47D11</scp> in patients with <scp>COVID</scp> ‐19-Reference-Cited by-同舟云学术

Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS‐CoV ‐2 neutralizing monoclonal antibody ABBV‐47D11 in patients with COVID ‐19

Published:2022-12-20 Issue:1 Volume:11 Page:
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacology Res & Perspec

Author:

Shebley Mohamad¹^ORCID,Wang Stanley¹,Ali Izna¹,Krishnan Preethi¹,Tripathi Rakesh¹,Reardon Joseph M.²^ORCID,Cafardi John³,Rahav Galia⁴,Caraco Yoseph⁵,Slim Jihad⁶,Al Akhrass Fadi⁷,Yu Mengjia¹,Hu Yiran¹,Ferreira Rosa De Abreu¹,Alami Negar N.¹

Affiliation:

1. AbbVie Inc. North Chicago Illinois USA

2. Prisma Health Upstate Greenville South Carolina USA

3. The Christ Hospital Cincinnati Ohio USA

4. Sheba Medical Center and Tel‐Aviv University Tel Hashomer Israel

5. Hadassah‐Hebrew University Medical Center Jerusalem Israel

6. NYMC Valhalla New York USA

7. Pikeville Medical Center Pikeville Kentucky USA

Funder

AbbVie

Publisher

Wiley